Cargando…
A physiologically based pharmacokinetic model for ionic silver and silver nanoparticles
Silver is a strong antibiotic that is increasingly incorporated into consumer products as a bulk, salt, or nanosilver, thus potentially causing side-effects related to human exposure. However, the fate and behavior of (nano)silver in the human body is presently not well understood. In order to aggre...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3771750/ https://www.ncbi.nlm.nih.gov/pubmed/24039420 http://dx.doi.org/10.2147/IJN.S46624 |
_version_ | 1782284216867749888 |
---|---|
author | Bachler, Gerald von Goetz, Natalie Hungerbühler, Konrad |
author_facet | Bachler, Gerald von Goetz, Natalie Hungerbühler, Konrad |
author_sort | Bachler, Gerald |
collection | PubMed |
description | Silver is a strong antibiotic that is increasingly incorporated into consumer products as a bulk, salt, or nanosilver, thus potentially causing side-effects related to human exposure. However, the fate and behavior of (nano)silver in the human body is presently not well understood. In order to aggregate the existing experimental information, a physiologically based pharmacokinetic model (PBPK) was developed in this study for ionic silver and nanosilver. The structure of the model was established on the basis of toxicokinetic data from intravenous studies. The number of calibrated parameters was minimized in order to enhance the predictive capability of the model. We validated the model structure for both silver forms by reproducing exposure conditions (dermal, oral, and inhalation) of in vivo experiments and comparing simulated and experimentally assessed organ concentrations. Therefore, the percutaneous, intestinal, or pulmonary absorption fraction was estimated based on the blood silver concentration of the respective experimental data set. In all of the cases examined, the model could successfully predict the biodistribution of ionic silver and 15–150 nm silver nanoparticles, which were not coated with substances designed to prolong the circulatory time (eg, polyethylene glycol). Furthermore, the results of our model indicate that: (1) within the application domain of our model, the particle size and coating had a minor influence on the biodistribution; (2) in vivo, it is more likely that silver nanoparticles are directly stored as insoluble salt particles than dissolve into Ag(+); and (3) compartments of the mononuclear phagocytic system play a minor role in exposure levels that are relevant for human consumers. We also give an example of how the model can be used in exposure and risk assessments based on five different exposure scenarios, namely dietary intake, use of three separate consumer products, and occupational exposure. |
format | Online Article Text |
id | pubmed-3771750 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-37717502013-09-13 A physiologically based pharmacokinetic model for ionic silver and silver nanoparticles Bachler, Gerald von Goetz, Natalie Hungerbühler, Konrad Int J Nanomedicine Original Research Silver is a strong antibiotic that is increasingly incorporated into consumer products as a bulk, salt, or nanosilver, thus potentially causing side-effects related to human exposure. However, the fate and behavior of (nano)silver in the human body is presently not well understood. In order to aggregate the existing experimental information, a physiologically based pharmacokinetic model (PBPK) was developed in this study for ionic silver and nanosilver. The structure of the model was established on the basis of toxicokinetic data from intravenous studies. The number of calibrated parameters was minimized in order to enhance the predictive capability of the model. We validated the model structure for both silver forms by reproducing exposure conditions (dermal, oral, and inhalation) of in vivo experiments and comparing simulated and experimentally assessed organ concentrations. Therefore, the percutaneous, intestinal, or pulmonary absorption fraction was estimated based on the blood silver concentration of the respective experimental data set. In all of the cases examined, the model could successfully predict the biodistribution of ionic silver and 15–150 nm silver nanoparticles, which were not coated with substances designed to prolong the circulatory time (eg, polyethylene glycol). Furthermore, the results of our model indicate that: (1) within the application domain of our model, the particle size and coating had a minor influence on the biodistribution; (2) in vivo, it is more likely that silver nanoparticles are directly stored as insoluble salt particles than dissolve into Ag(+); and (3) compartments of the mononuclear phagocytic system play a minor role in exposure levels that are relevant for human consumers. We also give an example of how the model can be used in exposure and risk assessments based on five different exposure scenarios, namely dietary intake, use of three separate consumer products, and occupational exposure. Dove Medical Press 2013 2013-09-02 /pmc/articles/PMC3771750/ /pubmed/24039420 http://dx.doi.org/10.2147/IJN.S46624 Text en © 2013 Bachler et al, publisher and licensee Dove Medical Press Ltd This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited. |
spellingShingle | Original Research Bachler, Gerald von Goetz, Natalie Hungerbühler, Konrad A physiologically based pharmacokinetic model for ionic silver and silver nanoparticles |
title | A physiologically based pharmacokinetic model for ionic silver and silver nanoparticles |
title_full | A physiologically based pharmacokinetic model for ionic silver and silver nanoparticles |
title_fullStr | A physiologically based pharmacokinetic model for ionic silver and silver nanoparticles |
title_full_unstemmed | A physiologically based pharmacokinetic model for ionic silver and silver nanoparticles |
title_short | A physiologically based pharmacokinetic model for ionic silver and silver nanoparticles |
title_sort | physiologically based pharmacokinetic model for ionic silver and silver nanoparticles |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3771750/ https://www.ncbi.nlm.nih.gov/pubmed/24039420 http://dx.doi.org/10.2147/IJN.S46624 |
work_keys_str_mv | AT bachlergerald aphysiologicallybasedpharmacokineticmodelforionicsilverandsilvernanoparticles AT vongoetznatalie aphysiologicallybasedpharmacokineticmodelforionicsilverandsilvernanoparticles AT hungerbuhlerkonrad aphysiologicallybasedpharmacokineticmodelforionicsilverandsilvernanoparticles AT bachlergerald physiologicallybasedpharmacokineticmodelforionicsilverandsilvernanoparticles AT vongoetznatalie physiologicallybasedpharmacokineticmodelforionicsilverandsilvernanoparticles AT hungerbuhlerkonrad physiologicallybasedpharmacokineticmodelforionicsilverandsilvernanoparticles |